Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01032018 · ClinicalTrials.gov registry record · Phase 1
Comparison of Depression Interventions After Acute Coronary Syndrome
A Phase 1 study of Depression and Acute Coronary Syndrome, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 5
- Study locations
NCT01032018 is a Phase 1 study of Depression and Acute Coronary Syndrome that has completed, run by Columbia University. The registered enrollment target is 150 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT01032018, a Phase 1 study of Depression and Acute Coronary Syndrome, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 5
- Study locations
Study Summary
Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI\>=15 or BDI\>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility criteria will be consented. Through informed consent, both arms of the trial will be described with equipoise as to these approaches to postACS depression care. Patients who consent to randomization will be enrolled in the treatment trial. The intervention phase will be 6 months, and hence the final outcome assessments will be performed approximately 9 months after the index ACS. Interim measures of depression will be obtained at 2 and 4 months post-enrollment. Major adverse cardiac events and all-cause mortality will also be ascertained at 6 months post-enrollment. Quality assurance by an independent medical event adjudication committee using prospective guidelines will be employed.
Conditions Studied
Interventions
- OTHER Standard care
- BEHAVIORAL Problem Solving Therapy
- DRUG Sertraline, citalopram, or bupropion
Study Locations (5)
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Missouri
- Washington University - St Louis
New York
- Columbia University Medical Center - New York
Pennsylvania
- Trustees of the University of Pennsylvania, Penn Cardiac Center at Mercer Bucks - Yardley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01032018
The ClinicalTrials.gov registry entry for NCT01032018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Standard care is the first listed.
NCT01032018 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT01032018 about?
NCT01032018 is a clinical study titled "Comparison of Depression Interventions After Acute Coronary Syndrome". Patients will be consented and screened within 2 to 6 months of the index ACS. Patients who have elevated depression (BDI\>=15 or BDI\>=10 assessed twice over two week period) and who continue to meet all of the trial's eligibility criteria will be consented. Through informed consent, both arms of t...
What is the current status of trial NCT01032018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2010-01. Estimated completion is 2012-07.
What conditions does trial NCT01032018 study?
This clinical trial studies the following conditions: Depression, Acute Coronary Syndrome.
What interventions are being tested in trial NCT01032018?
The interventions under investigation include: Standard care (OTHER), Problem Solving Therapy (BEHAVIORAL), Sertraline, citalopram, or bupropion (DRUG).
Who is sponsoring clinical trial NCT01032018?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01032018 being conducted?
This trial has 5 study locations across Connecticut, Georgia, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
RECRUITING · Phase 1
-
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
RECRUITING · Phase 1
-
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.